Document is current
Any future updates will be listed below
-
Authors
Solà Colom, Mireia
Fu, Zhenglin https://orcid.org/0000-0002-2574-3412
Gunkel, Philip https://orcid.org/0000-0003-4287-9482
Güttler, Thomas https://orcid.org/0000-0002-1456-7310
Trakhanov, Sergei
Srinivasan, Vasundara https://orcid.org/0000-0002-8895-5885
Gregor, Kathrin https://orcid.org/0009-0009-7178-3747
Pleiner, Tino https://orcid.org/0000-0002-5104-0315
Görlich, Dirk https://orcid.org/0000-0002-4343-5210
-
Funding
Funding for this research was provided by:
Boehringer Ingelheim Fonds
ERC (StuDySARCOMERE)
- License Information
-
More Information
Article History
Received: 12 September 2023
Revised: 11 March 2024
Accepted: 13 March 2024
First Online: 22 April 2024
Disclosure and competing interests statement
: MSC, KG, and DG are listed as inventors on a European patent application related to the use of anti-human NPC nanobodies. The remaining authors declare no competing interests.
